Title of Abstract Goes Here Please Make Sure RTOG and Study Number is Listed in Title

1
Title of Abstract Goes Here Please Make Sure
RTOG and Study Number is Listed in Title
E.P. Mitchell,1 K. Winter,2 M. Mohiuddin,3 N.
Hanna,3 A. Yuen,2 C. Nichols,4 R. Share,4 C.
Hayostek,2 C. Willett
1Thomas Jefferson University, Philadelphia, Penn
2Radiation Therapy Oncology Group, Philadelphia
3University of Kentucky, Lexington, Ky 4Reading
Hospital, Reading, Penn 5Massachusetts General
Hospital, Boston, Mass
ABSTRACT
OBJECTIVES
RESULTS
Background sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample sample sample sample sample sample sample
sample was performed 410 weeks following
completion of therapy. following completion of
therapy. following completion of therapy.
following completion of therapy. following
completion of therapy. following completion of
therapy.. Methods Patients with tumors Patients
with tumors Patients with tumors Patients with
tumors Patients with tumors Patients with tumors
Patients with tumors Patients with tumors
Patients with tumors Patients with
tumors. Results 106 patients were enrolled 106
patients were enrolled 106 patients were enrolled
106 patients were enrolled 106 patients were
enrolled 106 patients were enrolled 106 patients
were enrolled 106 patients were enrolled 106
patients were enrolled 106 patients were enrolled
106 patients were enrolled 106 patients were
enrolled 106 patients were enrolled 106 patients
were enrolled 106 patients were enrolled 106
patients were enrolled Conclusion Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable Both regimens
were well tolerated with acceptable

• Bullet Number One sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text.
• Bullet Number Two sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text.

• PATIENTS
• Bullet Number One sample text.
• Bullet Number Two sample text sample text.

Table IV. Patient Accrual sample text sample
text sample text 100 90 4 sample text sample
text sample text 100 90 4 sample text sample
text sample text 100 90 4
Table VII. Overall sample text sample text
sample text 100 sample text sample text sample
text 100 sample text sample text sample text
100
Table I. Patient Accrual sample text sample
text sample text 100 sample text sample text
sample text 100 sample text sample text sample
text 100
ELIGIBILITY

• Bullet Number One sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text.
• Bullet Number Two sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text.
• Bullet Number Three sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text

Table VIII. Causes of Death sample text sample
text sample text 100 sample text sample text
sample text 100 sample text sample text sample
text 100
SAFETY AND TOXICITY
Table V. Pretreatment sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400 sample text sample text
sample text 100 400
Table II. Pretreatment sample text sample text
sample text 100 sample text sample text sample
text 100 sample text sample text sample text
100 sample text sample text sample text 100

• CONCLUSIONS
• Sample text Sample text Sample text Sample text
  Sample text Sample text Sample text Sample text
  Sample text Sample text
• Sample text Sample text Sample text Sample text
  Sample text
• Sample text Sample text Sample text Sample text
  Sample text
• Sample text Sample text Sample text Sample text
  Sample text

STUDY DESIGN
Figure 1 Treatment Schema.
RANDOMIZATION
EFFICACY
Aim 1 Number One sample text sample text sample
text sample text sample sample text sample
text Number Two sample text sample text sample
text sample text sample sample text sample
text. Aim 2 Number One sample text sample text
sample text sample text sample sample text sample
text Number Two sample text sample text sample
text sample text sample sample text sample text.
BACKGROUND

• REFERENCES
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text.
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text
• Sample text sample text sample text sample text
  sample text sample text sample text sample text
  sample text sample text

Table III. Pathologic Response sample text
sample text sample text 100 sample text sample
text sample text 100 sample text sample text
sample text 100

• Bullet Number One sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text text sample text.
• Bullet Number Two sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text text sample text.
• Bullet Number Three sample text sample text
  sample text sample text sample sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text sample text sample text sample text sample
  text text sample text.

Table VI. Toxicities sample text sample text
sample text 100 sample text sample text sample
text 100 sample text sample text sample text
100